Expected Revenue Growth:
The global in situ hybridization market size is projected to reach USD 1.3 billion by 2025 from USD 0.9 billion in 2020, at a CAGR of 7.4% during the forecast period. The increasing incidence of cancer and genetic disorder and awareness of ISH based companion diagnostics tests are the major factors driving the growth of this market.
The cancer diagnostic segment accounted for the largest share of the application segment in the ISH market
Based on the application, the in situ hybridization market is segmented broadly into cancer diagnostics, cytology, infectious disease diagnostics, neuroscience, and immunology. The cancer diagnostics segment accounted for the largest share of the global market. This can be attributed to the high demand of FISH in the detection of cellular and genetic markers in cancers such as HER2, ALK, and ROS.
Download PDF Brochure@
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=212028829
Hospitals & diagnostic laboratories accounted for the fastest-growing end user segment of the ISH market
Based on the end user, the in situ hybridization market is segmented into hospital & diagnostic laboratories, academic & research institutes, CROs, and pharmaceutical & biotechnology companies. The hospital & diagnostic laboratories segment accounted for the largest share of the ISH market in 2019. This can be attributed to the increasing number of molecule-based screening, increasing number of specialty diagnostic tests performed in hospital laboratories, the rising number of in-house diagnostic procedures, and the rising trend of establishing in-house diagnostic capabilities in hospitals.
North America accounted for the largest share of the ISH market
North America accounted for the largest share of the global in situ hybridization market, followed by Europe. The large share of the North American region can be attributed to the presence of major players operating in the ISH market in the US, the rising incidence of cancer and infectious diseases, and the increasing adoption of CDx assay kits.
The prominent players operating in the in situ hybridization market are Abbott Laboratories (US), F. Hoffmann-La Roche Ltd (Switzerland), Agilent Technologies, Inc. (US), and Danaher Corporation (US).
Abbott Laboratories (US) has the largest market share in the in situ hybridization market. The company has gained its leadership through its VYSIS FISH platform and provides products and software for different types of cancer and prenatal and postnatal diagnosis. The company focuses on launching technologically advanced and innovative products in the market, such as kits, reagents, buffers, probes, and accessories. With its wide product portfolio, constant focus on R&D activities, and strategic collaborations, the company has created a strong foothold in the ISH market. The company has a strong presence in North America and the APAC and distribution networks and subsidiaries
Roche (Switzerland) is a world leader in IVD and tissue-based cancer diagnostics. The company has revolutionized cancer diagnostics across the globe through its cutting-edge testing automation. The company’s portfolio of more than 250 cancer tests and associated instruments makes it the leading global supplier of cancer diagnostic systems to the pathology market. The company’s new launches were focused mainly on cancer diagnostics. Its recent collaborations demonstrate a focus on expanding its diagnostic business and increasing accessibility for customers. Roche has shown a focus on differentiating its products in this market—as evident from the company’s emphasis on product innovation. It has launched innovative products over the last three years. For example, in 2019, the company introduced the VENTANA HER2 Dual ISH companion diagnostic test.
Request Sample Pages@
https://www.marketsandmarkets.com/requestsampleNew.asp?id=212028829
